Lv5
1200 积分 2022-08-31 加入
Efficacy and Safety of Camrelizumab Plus Apatinib in Patients With Refractory Chordoma: A Phase II Clinical Tria
2天前
已完结
Tucidinostat Plus R-CHOP vs R-CHOP in MYC/BCL2 Double-Expressor Diffuse Large B-Cell Lymphoma: A Randomized Clinical Trial
23天前
已完结
Efficacy and hypoglycemia-related safety of henagliflozin or dapagliflozin as add-on to CSII in hospitalized patients with T2DM: A retrospective matched study using continuous glucose monitoring
1个月前
已完结
Endothelin Receptor Antagonist Ambrisentan, SGLT2 Inhibitor Henagliflozin, and Their Combination in IgA Nephropathy A Randomized Crossover Trial
1个月前
已完结
Retlirafusp Alfa: First Approval
1个月前
已完结
A Multicentre, Randomised, Controlled, Open-Label Study of Continuous Subcutaneous Insulin Infusion Plus Henagliflozin for Treating Type 2 Diabetes Mellitus Patients With Severe Hyperglycaemia
1个月前
已完结
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study
1个月前
已完结
Society of Surgical Oncology SSO 2026 Annual Meeting
2个月前
已完结
Fuzuloparib plus apatinib in BRCA-mutated breast cancer: balancing efficacy and accessibility in regional China
2个月前
已完结
Trastuzumab Rezetecan in Human Epidermal Growth Factor Receptor 2-Expressing Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma and Colorectal Cancer: A Multicenter, Open-Label, Phase I Trial
2个月前
已完结
皖公网安备34019202002308
